Susquehanna International Group, LLP Vyne Therapeutics Inc. Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.12 - $4.91 $1,013 - $41,460	-8,444 Reduced 33.87%	16,484 $2,000
Q3 2022 Nov 14, 2022	BUY	$0.24 - $4.27 $5,982 - $106,442	24,928 New	24,928 $6,000
Q2 2022 Aug 15, 2022	SELL	$0.37 - $0.71 $3,784 - $7,262	-10,229 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.5 - $1.15 $17,550 - $40,366	-35,101 Reduced 77.43%	10,229 $7,000
Q4 2021 Feb 14, 2022	BUY	$0.91 - $1.5 $28,240 - $46,549	31,033 Added 217.06%	45,330 $46,000
Q3 2021 Nov 15, 2021	SELL	$1.39 - $3.47 $46,267 - $115,502	-33,286 Reduced 69.95%	14,297 $20,000
Q2 2021 Aug 11, 2021	BUY	$3.24 - $6.92 $154,168 - $329,274	47,583 New	47,583 $167,000

36.5K

Ticker VYNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,005,600
Market Cap $179M
Description
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, whi...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.